Finasteride

CLINICAL USE

Benign prostatic hypertrophy Male pattern baldness

DOSE IN NORMAL RENAL FUNCTION

BPH: 5 mg dailyMale pattern baldness: 1 mg daily

PHARMACOKINETICS

  • Molecular weight                           :372.5
  • %Protein binding                           :≈93
  • %Excreted unchanged in urine     : <0.05
  • Volume of distribution (L/kg)       :1.07
  • half-life – normal/ESRD (hrs)      :6–8/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Data sheet states that no dosage adjustment is required in renally impaired patients whose creatinine clearance is as low as 9 mL/min. No studies have been done in patients with creatinine clearance of less than 9 mL/min

  • Related News